Advocates press California governor to reverse Medi-Cal obesity drug cut
The Almanac · 2026-09-13
Medicaid
California's Medi-Cal program is facing pressure to restore coverage for GLP-1 medications for obesity. The program cut coverage for these drugs in its 2026 budget, a move advocates argue harms low-income patients with obesity, a condition directly linked to diabetes, heart disease, and other costly chronic illnesses. This coverage gap creates a two-tiered system where commercially insured patients can access these treatments but Medicaid beneficiaries cannot, worsening health disparities. The pushback illustrates the growing political tension over high-cost, high-demand pharmaceuticals in public programs as budget pressures mount. Monitor for any executive action from the governor's office to address the coverage cut.
Related references